论文部分内容阅读
目的:研究乳腺癌组织中Ezrin、AKT2的表达及其与临床病理指标和预后的关系。方法:应用免疫组化SP法,检测56例乳腺癌组织、30例癌旁正常乳腺组织石蜡切片中Ezrin、AKT2的表达,并分析各蛋白分子的表达与临床病理学指标之间的关系。结果:①乳腺癌组织中Ezrin、AKT2的表达率分别为62.50%和76.79%,与正常乳腺组织相比差异有统计学意义(P<0.05)。②Ezrin的表达与乳腺癌的组织学分级、临床TNM分期和淋巴结转移有关(P<0.05)。AKT2的表达与乳腺癌的淋巴结转移有关(P<0.05)。③在乳腺浸润性导管癌中Ezrin与AKT2表达水平呈显著正相关(P<0.05)。结论:Ezrin、AKT2高表达与乳腺癌的发生、发展及浸润转移有关,可作为判断乳腺癌生物学行为和预后的重要指标。
Objective: To study the expression of Ezrin and AKT2 in breast cancer and its relationship with clinicopathological parameters and prognosis. Methods: Immunohistochemical SP method was used to detect the expression of Ezrin and AKT2 in 56 cases of breast cancer tissues and 30 cases of adjacent normal breast tissues. The relationship between the expression of Ezrin and AKT2 protein and clinicopathological parameters was analyzed. Results: ① The expression rates of Ezrin and AKT2 in breast cancer tissues were 62.50% and 76.79%, respectively, which were significantly different from those in normal breast tissues (P <0.05). ② The expression of Ezrin was correlated with histological grade, TNM staging and lymph node metastasis in breast cancer (P <0.05). AKT2 expression was correlated with lymph node metastasis in breast cancer (P <0.05). (3) There was a significant positive correlation between Ezrin and AKT2 expression in invasive ductal carcinoma (P <0.05). Conclusion: The high expression of Ezrin and AKT2 is associated with the occurrence, development and infiltration and metastasis of breast cancer, which may be used as an important index to judge the biological behavior and prognosis of breast cancer.